Articles related to GASTRO/HEP DISORDERS

Dive into this CME program to grasp the latest C. difficile guidelines and implement treatment strategies effectively. This interactive CME program focuses on Clostridioides difficile, or C. difficile. As you know, this bacterium causes severe GI disturbances. Alarmingly, it impacts half a million Americans annually and burdens the healthcare system. Who is this for? Infectious disease physicians, gastroenterologists, hospitalists, intensivists, and all HCPs managing patients with C. difficile infection (CDI) will benefit greatly. Initially, the program offers a comprehensive review of CDI. It presents the epidemiology and pinpoints key risk factors. Moreover, it explains the underlying pathophysiology and outlines clinical features. Significantly, it emphasizes the disease’s burden and unveils diagnostic tools, including NAAT, GDH assay, and toxin tests. Following this, the program shifts to treatment strategies for CDI. It details procedures for various severity levels – mild, severe, fulminant, and recurrent. Concurrently, it underlines the common challenges in therapy decision-making. Importantly, it stresses the necessity of adhering to CDI guidelines and presents preventative measures. In the concluding section, participants receive practical patient cases. This allows the application of newfound knowledge directly. Afterward, it wraps up with a summary and a best practice recap. Upon completion, participants will grasp the burden […]

Medtronic is collaborating with Nvidia on developing means to allow AI to run on its devices. The solution will use Nvidia chips on Medtronic devices and an AI layer that would allow doctors to create their own algorithms to run on the machines. The first will be implemented on the GI Genius endoscopy module. Medtronic hopes the strategy will mean that millions of users around the globe will be contributing to making their devices more capable and flexible for the diversity of real-world clinic challenges.

Manuka honey contains amino acids, B-vitamins, calcium, copper, iron, magnesium, potassium, sodium, and zinc. It has antibacterial, antiviral, anti-inflammatory, and antioxidant properties. Besides use in wound infection, it may be useful in treating some GI disorders and sore throats.

The timing of re-initiation of antithrombotic therapy needs to be individualized based on the severity of the bleed, among other factors. This article reviews the issue and offers tools and guidelines for determining if and when to restart antiplatelet and oral anticoagulant therapy.

Working from the hypothesis that stomach ulcer bleeds in people on long-term low-dose aspirin therapy was secondary to H. pylori infection, this team gave antibiotic treatment to aspirin takers who test positive for the bacteria, and followed them for up to 7 years. Protection started rapidly and persisted, while diminishing somewhat, over the period of observation.

The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.